StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reaffirmed a buy rating and issued a $9.00 price objective on shares of Trevena in a research report on Tuesday, April 2nd.
View Our Latest Stock Report on Trevena
Trevena Stock Performance
Institutional Investors Weigh In On Trevena
A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC acquired a new stake in shares of Trevena, Inc. (NASDAQ:TRVN – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned approximately 0.32% of Trevena at the end of the most recent reporting period. 13.56% of the stock is owned by hedge funds and other institutional investors.
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
See Also
- Five stocks we like better than Trevena
- How to Buy Cheap Stocks Step by Step
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- What is the Dogs of the Dow Strategy? Overview and Examples
- Merger or Not, Albertson’s Companies is a Good Buy
- Upcoming IPO Stock Lockup Period, Explained
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.